title: [Pancreatitis during treatment of leishmaniasis with n-methylglucamine antimoniate in a subject infected with HIV].
abstract: In this study the authors report the case of HIV patients with visceral leishmaniasis. He presented a pancreatitis with evident clinical signs and high increase of amilasis (9876 U/L) the twelfth day of treatment with meglumine antimoniate. The interruption of therapy was followed by a rapid disappearance of signs and symptoms and a normalization of amilasis. In accordance with the most recent studies, it is expedient, for every patients treated with antimonial drugs, to undergo an accurate amilasis monitoring.
authors.affiliation: Dipartimento di Mallattie Infettive e Tropicali, Università degli Studi La Sapienza, Roma.
authors.forename: V
authors.initials: V
authors.lastname: Trinchieri
authors.forename: U
authors.initials: U
authors.lastname: Ferone
authors.forename: M
authors.initials: M
authors.lastname: Monacelli
authors.forename: L
authors.initials: L
authors.lastname: Isceri
authors.forename: F
authors.initials: F
authors.lastname: Proietti
authors.forename: F
authors.initials: F
authors.lastname: Sorice
mesh_terms: D000328:Adult; D000965:Antimony / Q000009:adverse effects* / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007896:Leishmaniasis / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008536:Meglumine / Q000009:adverse effects* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D010195:Pancreatitis / Q000139:chemically induced* / Q000150:complications
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony